Therapeutic Area Various



To develop cell-based tools to screen for pharmacoactive molecules that bind to GPCRs and to define ligand-biased signalling signatures

Type of Target G Protein-Coupled Receptors (GPCR desensitization and G protein-independent signallling)
IP Status US patent №. 7,932,080 granted
Principal Investigator Michel Bouvier

Competitive Advantages

• Signalling signature profiles in homogeneous assay format
• Wide coverage of GPCR signalling pathways
• Clustering of ligands based on activity profiles
• Applicable to established cell lines or primary cultures
• Amenable to HTS, hit-to-lead and lead-optimization